{"id":"homologous-mrna-booster-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or swelling"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This vaccine uses messenger RNA technology to express viral spike protein or related antigens, designed to boost and diversify the T-cell and B-cell responses elicited by primary COVID-19 vaccination. By using a homologous (same-platform) mRNA approach, it aims to reinvigorate waning immunity and improve protection against emerging variants through repeated antigenic stimulation.","oneSentence":"A homologous mRNA booster vaccine that encodes viral antigens to enhance and broaden immune responses in individuals previously vaccinated against COVID-19.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:22:37.280Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 booster vaccination in previously vaccinated individuals"}]},"trialDetails":[{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT05148962","phase":"PHASE1","title":"Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Gritstone bio, Inc.","startDate":"2021-09-16","conditions":"COVID-19","enrollment":45},{"nctId":"NCT05142319","phase":"PHASE4","title":"Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC]","status":"COMPLETED","sponsor":"Tan Tock Seng Hospital","startDate":"2021-10-12","conditions":"COVID-19","enrollment":326},{"nctId":"NCT05593042","phase":"PHASE2","title":"Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-11-28","conditions":"COVID-19, Vaccines","enrollment":551},{"nctId":"NCT04826770","phase":"","title":"Adaptive Immune Response to COVID-19 Vaccination","status":"UNKNOWN","sponsor":"University Medicine Greifswald","startDate":"2021-01-06","conditions":"SARS-CoV-2 Vaccination","enrollment":70},{"nctId":"NCT05609045","phase":"PHASE1","title":"A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster","status":"WITHDRAWN","sponsor":"Wuhan Rhegen Biotechnology Co., Ltd.","startDate":"2023-06","conditions":"COVID-19 Pandemic","enrollment":""},{"nctId":"NCT05081271","phase":"EARLY_PHASE1","title":"COVID-19 Booster Vaccination in Persons With Multiple Sclerosis","status":"TERMINATED","sponsor":"Griffin Hospital","startDate":"2021-10-15","conditions":"Multiple Sclerosis","enrollment":10},{"nctId":"NCT05547802","phase":"","title":"Serology After BBIBP-CorV Inactivated Vaccine Combined With BNT62b2 mRNA Booster Vaccine","status":"COMPLETED","sponsor":"University of Debrecen","startDate":"2021-11-16","conditions":"Basic BBIBP-CorV Vaccination is Not as Effective as BNT162b","enrollment":122},{"nctId":"NCT04993560","phase":"","title":"Safety and Efficacy of COVID-19 Prime-boost Vaccine in Bahrain","status":"COMPLETED","sponsor":"Royal College of Surgeons in Ireland - Medical University of Bahrain","startDate":"2021-07-18","conditions":"SARS-CoV 2 Infection, Covid19","enrollment":305}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Homologous mRNA booster vaccine","genericName":"Homologous mRNA booster vaccine","companyName":"Tan Tock Seng Hospital","companyId":"tan-tock-seng-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"A homologous mRNA booster vaccine that encodes viral antigens to enhance and broaden immune responses in individuals previously vaccinated against COVID-19. Used for COVID-19 booster vaccination in previously vaccinated individuals.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}